Sana Biotechnology (NASDAQ:SANA) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a market perform rating to an outperform rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. Citizens Jmp currently has $5.00 price objective on the stock.

Several other brokerages have also recently weighed in on SANA. HC Wainwright lifted their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Price Performance

Shares of SANA opened at $2.26 on Tuesday. The firm has a 50-day moving average of $2.98 and a 200-day moving average of $3.19. Sana Biotechnology has a one year low of $1.52 and a one year high of $10.50. The company has a market cap of $504.59 million, a PE ratio of -1.61 and a beta of 1.63.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current year.

Insider Activity

In related news, insider Fmr Llc sold 290,912 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This represents a 6.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cornercap Investment Counsel Inc. acquired a new position in Sana Biotechnology in the 3rd quarter valued at approximately $67,000. Intech Investment Management LLC acquired a new position in Sana Biotechnology in the 3rd quarter valued at approximately $240,000. Charles Schwab Investment Management Inc. increased its position in Sana Biotechnology by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock valued at $4,359,000 after acquiring an additional 105,382 shares during the period. FMR LLC increased its position in Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after acquiring an additional 4,438,949 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sana Biotechnology by 17.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after acquiring an additional 5,338 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.